D. Boral Capital Reaffirms “Buy” Rating for Can-Fite BioPharma (NYSE:CANF)

Posted by ABMN Staff on Dec 31st, 2024

Can-Fite BioPharma (NYSE:CANF – Get Free Report)‘s stock had its “buy” rating reissued by analysts at D. Boral Capital in a research note issued to investors on Tuesday,Benzinga reports. They presently have a $10.00 price target on the stock.

A number of other equities research analysts also recently weighed in on CANF. HC Wainwright reiterated a “buy” rating and issued a $18.00 price objective on shares of Can-Fite BioPharma in a research note on Tuesday, November 12th. StockNews.com cut Can-Fite BioPharma from a “hold” rating to a “sell” rating in a research report on Friday, December 13th.

Get Our Latest Analysis on Can-Fite BioPharma

Can-Fite BioPharma Stock Performance

Shares of NYSE:CANF traded up $0.04 during midday trading on Tuesday, hitting $1.58. The company’s stock had a trading volume of 9,208 shares, compared to its average volume of 157,845. The stock’s 50 day simple moving average is $1.92 and its 200 day simple moving average is $2.38. Can-Fite BioPharma has a fifty-two week low of $1.29 and a fifty-two week high of $4.69. The stock has a market capitalization of $5.58 million, a price-to-earnings ratio of -0.88 and a beta of 1.32.

Hedge Funds Weigh In On Can-Fite BioPharma

A hedge fund recently raised its stake in Can-Fite BioPharma stock. Armistice Capital LLC grew its position in shares of Can-Fite BioPharma Ltd. (NYSE:CANF – Free Report) by 35.5% in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 518,853 shares of the company’s stock after acquiring an additional 136,055 shares during the quarter. Armistice Capital LLC owned 14.66% of Can-Fite BioPharma worth $1,339,000 at the end of the most recent reporting period. 21.00% of the stock is currently owned by hedge funds and other institutional investors.

About Can-Fite BioPharma

(Get Free Report)

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19.